| domain | core finding/statistic | evidence type | source/date/DOI or NCT |
|---|---|---|---|
| Disease identifiers | Generalized resistance to thyroid hormone; MONDO:0009043; OMIM:188570; disease-level aggregated rare-disease/gene-disease resources link generalized RTH to **THRB** (pqac-00000000, pqac-00000002) | Ontology/database + guideline | Open Targets disease-target association context; ETA Guideline, Jul 2024, https://doi.org/10.1530/etj-24-0125 |
| Core definition | RTHβ is characterized by elevated thyroid hormones with non-suppressed TSH and variable multisystem phenotype from asymptomatic to thyrotoxic (pqac-00000002, pqac-00000008) | Guideline/reviewed clinical evidence | ETA Guideline, Jul 2024, DOI:10.1530/etj-24-0125 |
| Causal gene / inheritance | Causal gene: **THRB**; typically **autosomal dominant**; mutant TRβ acts in a **dominant-negative** manner via reduced hormone binding and/or impaired corepressor release/coactivator recruitment (pqac-00000002, pqac-00000009) | Mechanistic human/genetic guideline evidence | ETA Guideline, Jul 2024, DOI:10.1530/etj-24-0125 |
| Prevalence | Reported prevalence range **~1:18,750 to 1:40,000** (pqac-00000003, pqac-00000006) | Human cohort + case report summary | Büyükyılmaz et al., Dec 2024, DOI:10.4274/jcrpe.galenos.2024.2024-8-14; Belal et al., Oct 2024, DOI:10.1210/jendso/bvae163.2063 |
| Variant spectrum | Turkish series found **8 heterozygous pathogenic/likely pathogenic missense variants** in 30 genetically confirmed patients from 8 unrelated families, including **3 novel variants** (pqac-00000003, pqac-00000004) | Human cohort | Büyükyılmaz et al., Dec 2024, DOI:10.4274/jcrpe.galenos.2024.2024-8-14 |
| Variant-negative fraction | About **10–15%** of clinically suspected/phenotypic RTHβ cases may lack an identifiable **THRB** variant; possible explanations include mosaicism or noncoding/deep intronic defects (pqac-00000002, pqac-00000005, pqac-00000006) | Guideline + cohort + case summary | ETA Guideline, Jul 2024, DOI:10.1530/etj-24-0125; Büyükyılmaz et al., Dec 2024, DOI:10.4274/jcrpe.galenos.2024.2024-8-14 |
| Biochemical hallmark | Typical diagnostic pattern: **elevated free/total T4**, **elevated free/total T3**, and **non-suppressed or inappropriately normal/elevated TSH** (pqac-00000002, pqac-00000008) | Guideline | ETA Guideline, Jul 2024, DOI:10.1530/etj-24-0125 |
| Differential diagnosis | Important differentials include **assay interference** and **TSH-secreting pituitary adenoma (TSHoma)**; in the Turkish suspected cohort, **1/20** variant-negative patients had TSHoma (pqac-00000004, pqac-00000006) | Cohort + case-based clinical evidence | Büyükyılmaz et al., Dec 2024, DOI:10.4274/jcrpe.galenos.2024.2024-8-14; Belal et al., Oct 2024, DOI:10.1210/jendso/bvae163.2063 |
| Pediatric/adult phenotype frequencies | In the 2024 Turkish genetically confirmed cohort (**n=30**): **56%** of children had goiter; **23%** had positive thyroid autoantibodies; **7 adults** had thyroid nodules; **2 adults** had papillary thyroid carcinoma (pqac-00000003, pqac-00000005) | Human cohort | Büyükyılmaz et al., Dec 2024, DOI:10.4274/jcrpe.galenos.2024.2024-8-14 |
| Clinical phenotype spectrum | Many patients are asymptomatic, but reported manifestations include goiter, tachycardia/tachyarrhythmia, anxiety, sleep disturbance, ADHD/learning issues, hearing loss, color vision impairment, dyslipidemia, and increased liver fat (pqac-00000002, pqac-00000004, pqac-00000006) | Guideline + cohort + case summary | ETA Guideline, Jul 2024, DOI:10.1530/etj-24-0125; Büyükyılmaz et al., Dec 2024, DOI:10.4274/jcrpe.galenos.2024.2024-8-14 |
| Cardiovascular prognosis | Guideline-level evidence notes increased risks of **atrial fibrillation, myocardial infarction, heart failure, and earlier mortality** in RTHβ, likely reflecting excess hormone action in TRα-expressing tissues such as myocardium (pqac-00000009) | Guideline/expert synthesis | ETA Guideline, Jul 2024, DOI:10.1530/etj-24-0125 |
| Management principles | Many patients require **no disease-specific therapy**; avoid antithyroid drugs or thyroid ablation unless significant comorbidity/misdiagnosis issues; treatment is individualized and symptom-directed (pqac-00000004, pqac-00000007) | Guideline + cohort | ETA Guideline, Jul 2024, DOI:10.1530/etj-24-0125; Büyükyılmaz et al., Dec 2024, DOI:10.4274/jcrpe.galenos.2024.2024-8-14 |
| TRIAC therapy | **TRIAC (triiodothyroacetic acid)** is recommended/used to control thyrotoxic signs and symptoms; guideline dosing reported as **1.4–2.8 mg twice or three times daily**, preferably with expert-center input (pqac-00000001, pqac-00000007) | Guideline/expert consensus | ETA Guideline, Jul 2024, DOI:10.1530/etj-24-0125 |
| Other symptomatic therapy | **Beta-blockade** can be used for adrenergic symptoms; selected reports note benefit of **alternate-day supraphysiologic liothyronine (D-T3)** for goiter/ADHD phenotypes (pqac-00000002, pqac-00000006) | Guideline + case summary | ETA Guideline, Jul 2024, DOI:10.1530/etj-24-0125; Belal et al., Oct 2024, DOI:10.1210/jendso/bvae163.2063 |
| Surveillance | Recommended follow-up includes **thyroid ultrasound**, **anti-thyroid antibodies**, cardiovascular assessment (BP, ECG ± echo, especially >30 y or symptomatic), **fasting lipids/glucose**, adult **bone density**, and pediatric growth/development/hearing/neuropsychological assessment (pqac-00000007, pqac-00000008) | Guideline | ETA Guideline, Jul 2024, DOI:10.1530/etj-24-0125 |
| Pregnancy | Women with RTHβ should receive **multidisciplinary endocrine-obstetric care**; monitoring should include fetal growth and heart rate; guideline notes increased **miscarriage** and **small-for-gestational-age** risk in affected mothers (pqac-00000001, pqac-00000007) | Guideline/expert synthesis | ETA Guideline, Jul 2024, DOI:10.1530/etj-24-0125 |
| Active observational study | **Understanding, Diagnosis and Monitoring of Thyroid Hormone Action Defects**; recruiting observational study; planned enrollment **150** (RTH and related thyroid hormone action defects) | Clinical study registry | **NCT06307990**, Istituto Auxologico Italiano, https://clinicaltrials.gov/study/NCT06307990 |
| Active registry | **Register for Patients With Thyroid Hormone Resistance**; recruiting observational registry; planned enrollment **200** | Clinical study registry | **NCT06566066**, Charité University Berlin, https://clinicaltrials.gov/study/NCT06566066 |
| Natural history platform | **Natural History of Thyroid Function Disorders**; recruiting observational study; planned enrollment **2500** | Clinical study registry | **NCT00001159**, NIH Clinical Center, https://clinicaltrials.gov/study/NCT00001159 |
| Mouse model evidence | TRβ mouse models show that **pituitary-thyroid negative feedback depends on TRβ DNA binding**; **severe hearing loss** occurs in TRβKO and TRβGS mice; retinal thickness/visual phenotypes support sensory-system involvement of TRβ (pqac-00000010) | Animal model | Hönes et al., bioRxiv, Nov 2024, DOI:10.1101/2023.11.26.568063 |
| Translational interpretation | Mouse data support human tissue selectivity: impaired central feedback and sensory phenotypes help explain unsuppressed TSH plus hearing/vision abnormalities seen clinically in RTHβ (pqac-00000002, pqac-00000010) | Cross-species synthesis | ETA Guideline, Jul 2024, DOI:10.1530/etj-24-0125; Hönes et al., Nov 2024, DOI:10.1101/2023.11.26.568063 |


*Table: This compact table summarizes high-value evidence for generalized resistance to thyroid hormone (RTHβ), emphasizing identifiers, genetics, biochemical diagnosis, recent cohort data, management, surveillance, ongoing studies, and translational animal findings.*